Our analysis indicates that common targeted therapies might be developed to treat serous-like EC and serous OvCa based on mutation drivers, such as PIK3CA. Equal amount of considerations, if not more, should be paid to on the gene expression, signal pathway activities and tumor microenvironment to investigate drug responsiveness and to identify novel molecular targets for them individually. The gene discussed is PIK3CA; the disease is neoplasm.